-
A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (POTEYK-SLE-1)
This is a Phase 3, randomized, parallel-arm, double-blind, PBO-controlled, multicenter 52-week clinical trial to evaluate the efficacy and safety of deucravacitinib in adult participants with ... -
A Phase 3 Open-Label Randomized Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced ... -
A Phase 3 Multi-center Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy
To evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH compared with placebo as measured by the OHSA composite score ... -
A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
This is a two-stage, Phase 3, randomized, multi-center, controlled, open-label study comparing iberdomide maintenance to lenalidomide maintenance therapy after ASCT in participants with newly diagnosed ... -
A randomised double-blind placebo-controlled multicentre Phase 3 study evaluating efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis
The 3 peroxisome proliferator-activated receptors (PPAR) isoforms play an important role in several components of NASH, from hepatic triglyceride accumulation to fibrosis. Lanifibranor, a pan-PPAR ... -
A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus
This is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of an SC treatment regimen of anifrolumab versus ... -
AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
The primary objective is to compare the PFS of patients with early-stage cHL treated through a response-adapted design with either standard therapy or with an ... -
A 52-week Double-blind Placebo-controlled Randomized Phase 3 study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study of seladelpar in patients with PBC and ALP values greater than ULN but less than 1 ... -
PRESERVE Heart Study
Heart transplantation has long proven success for the treatment of end stage organ disease, and preservation of the heart prior to transplant remains an important ... -
A PHASE 3 MULTI-CENTER RANDOMIZED DOUBLE-BLIND TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AFICAMTEN COMPARED TO PLACEBO IN ADULTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled trial in participants with symptomatic nHCM. Approximately 420 eligible participants will be randomized in a 1 ...